WWWei Wang

Wei Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Wang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Mei Tu

    Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China

    4 shared publications
  • Xiu Li Guo

    Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China

    4 shared publications
  • Xiu Ping Qiu

    Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China

    2 shared publications
  • Yang Chen

    Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China

    2 shared publications
  • Chuan Wang Li

    Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, 364000, People's Republic of China

    1 shared publication
  • Honglin Qiu

    Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, 364000, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Perirenal adipose tissue accumulation mediates the adverse impact of the atherogenic index of plasma on lower extremity peripheral arterial disease

    by Xiu Li Guo, Mei Tu, Xiu Ping Qiu, Wei Wang

    This study aims to evaluate the relationship between perirenal adipose tissue (PAT) accumulation and the risk of lower-extremity peripheral arterial disease (LEAD) and its potential mediating role in the association between the atherogenic index of plasma (AIP) and LEAD. 828 participants with type 2 diabetes mellitus (T2DM) were included in the final analysis. Perirenal fat thickness (PrFT) was assessed using unenhanced abdominal CT to estimate PAT mass. The diagnosis of LEAD was based on the ankle-brachial index (ABI), stenosis, or occlusion in the lower limb arteries. After full adjustment for potential confounders, PrFT negatively correlated with ABI (β = − 0.265, P < 0.001) and positively correlated with AIP (β = 0.121, P < 0.001). PrFT was identified as an independent risk factor for LEAD (OR 1.14, 95% CI 1.03–1.26, P = 0.010). Restricted cubic splines analysis further revealed a non-linear association between PrFT and risk of LEAD (P for overall = 0.015; P for nonlinear = 0.039). Additionally, PrFT mediated 15.9% and 12.5% of the adverse impacts of AIP on ABI and LEAD. Furthermore, sensitivity analyses excluding 141 newly diagnosed T2DM produced consistent results. PAT accumulation was independently associated with the risk of LEAD and partially mediated the adverse impacts of AIP on ABI and LEAD.


  • Open Access

    The serum uric acid to apolipoprotein A1 ratio is independently correlated with metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus: findings from a single national metabolic management center cohort

    by Xiu Li Guo, Mei Tu, Xiu Ping Qiu, Wei Wang

    Background: Recent evidence suggests that the serum uric acid to apolipoprotein A1 ratio (UAR) may be a novel biomarker for metabolic dysfunction-associated steatotic liver disease (MASLD). This study aims to investigate the relationship between UAR and MASLD, and compare the diagnostic ability of UAR with other insulin resistance-related markers for MASLD in individuals with type 2 diabetes mellitus (T2DM).Method: A cohort of 1,019 individuals with T2DM was recruited from the National Metabolic Management Center of our hospital. Unenhanced abdominal CT scans were performed to evaluate liver steatosis for diagnosing MASLD. The association between UAR and the risk of MASLD was analyzed using weighted binomial logistic regression, restricted cubic splines (RCS), and subgroup analysis. Receiver operating characteristic (ROC) curve analysis was conducted to compare the diagnostic performance of UAR with other insulin resistance-related markers, including the serum uric acid to high-density lipoprotein cholesterol ratio (UHR), triglyceride to high-density lipoprotein cholesterol ratio (THR), and triglyceride to apolipoprotein A1 ratio (TAR).Results: Participants in the MASLD group exhibited elevated UAR levels. After full adjustments for potential confounders, UAR remained independently associated with MASLD (OR: 1.65, 95% CI: 1.45-1.89, P < 0.001). Subgroup analyses revealed that this association was consistent across various subgroups, including sex, drinking status, hypertension, lipid-lowering therapy, and body mass index (P < 0.05). RCS analysis demonstrated a linear increase in the risk of MASLD with higher UAR levels (P for nonlinear = 0.319). ROC curve analysis indicated that UAR provided good diagnostic performance for MASLD (AUC:0.777, 95% CI: 0.749- 0.805), comparable to TAR (AUC difference: -0.003, 95% CI: -0.033-0.026, P = 0.818) and superior to UHR (AUC difference: 0.043, 95% CI: 0.019-0.067, P < 0.001) and THR (AUC difference: 0.035, 95% CI: 0.019-0.067, P = 0.047).Conclusion: UAR was independently associated with MASLD and demonstrated significant diagnostic value, indicating that UAR could be a cost-effective biomarker to help identify high-risk individuals for MASLD.


  • Open Access

    Perirenal fat thickness as a superior obesity-related marker of subclinical carotid atherosclerosis in type 2 diabetes mellitus

    by Xiu Li Guo, Jian Wen Wang, Mei Tu, Wei Wang

    Objective: Emerging evidence highlighted that perirenal adipose tissue might regulate the cardiovascular and metabolism system through several pathways. This study aimed to assess the association between perirenal fat thickness (PrFT) and subclinical carotid atherosclerosis (SCCA) in type 2 diabetes mellitus (T2DM).Method: A total of 670 participants with complete data were included in this study. The trained reviewer collected demographic and anthropometric information. Laboratory assessments were determined by standard methods. PrFT and SCCA were evaluated by computed tomography and ultrasound. Binomial logistic regression analysis was conducted to assess the association between PrFT and SCCA. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the identifying value of PrFT for SCCA.Results: Overall, the prevalence of SCCA was 61.8% in T2DM. PrFT was significantly increased in the SCCA group. Growing trends were observed in the prevalence of hypertension, carotid intima-media thickness (cIMT) > 1, plaque, and SCCA across the PrFT quartiles. Spearman correlation analysis revealed that PrFT was positively associated with cIMT (r = 0.401, p < 0.001). This correlation remained significant after adjustment for visceral fat area (VFA), subcutaneous fat area (SFA), and traditional metabolic risk factors (β = 0.184, p < 0.001). Meanwhile, PrFT was independently correlated with plaque, cIMT > 1 mm, and SCCA. The ORs (95% CI) were 1.072 (1.014–1.135), 1.319 (1.195–1.455), and 1.216 (1.119–1.322). Furthermore, PrFT remained correlated considerably with SCCA in subgroup analysis after stratification for age, sex, smoking, hypertension, and body mass index. From the ROC curve analysis, the AUCs (95% CI) of PrFT, VFA, and SFA identifying SCCA were 0.794 (0.760–0.828), 0.760 (0.724–0.796), and 0.697 (0.656–0.737), respectively. The AUC of PrFT was significantly higher than VFA (p = 0.028) and SFA (p < 0.001). The optimal cutoff values of PrFT were 14.0 mm, with a sensitivity of 66.7% and a specificity of 76.2%.Conclusion: PrFT was independently associated with cIMT, plaque, cIMT > 1 mm, and SCCA as a superior obesity-related marker of SCCA in T2DM.Clinical trial registration: Clinical Trials.Gov, identifier ChiCTR2100052032.


  • Open Access

    Perirenal Fat Thickness is Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus

    by Jian Yang, Chuan Wang Li, Jing Ru Zhang, Honglin Qiu, Xiu Li Guo, Wei Wang

    Objective: Recent advances in perirenal adipose tissue (PAT) highlighted that PAT might involve in the pathogenesis of chronic inflammatory and dysfunctional metabolic diseases. This study assessed the association between perirenal fat thickness (PrFT) and metabolic dysfunction-associated fatty liver disease (MALFD) in type 2 diabetes mellitus (T2DM). Methods: This study comprised 867 eligible participants with T2DM. Trained reviewers collected anthropometric and biochemical measurements. The diagnosis of MAFLD was based on the latest international expert consensus statement. PrFT and fatty liver were evaluated by computed tomography. The visceral fat area (VFA) and subcutaneous fat area (SFA) were measured by bioelectrical impedance analysis. The non-alcoholic fatty liver disease fibrosis score (NFS) and fibrosis-4 (FIB-4) index were used to assess progressive liver fibrosis in MAFLD. Results: Overall, the prevalence of MAFLD was 62.3% in T2DM. The PrFT in the MAFLD group was statistically increased than in the non-MAFLD group (P < 0.05). Correlation analysis showed that PrFT was significantly correlated with dysfunctional metabolic factors like body mass index, waist circumference, triglycerides, high-density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure, uric acid, and insulin resistance. Multiple regression analysis revealed that PrFT was positively correlated with NFS (β=0.146, P< 0.001) and FIB-4 (β=0.082, P=0.025) in the MAFLD. In contrast, PrFT was negatively correlated with CTL-S (β=− 0.188, P< 0.001). Furthermore, PrFT was also significantly associated with MAFLD independent of VFA and SFA, the OR (95% CI) was 1.279 (1.191– 1.374). Meanwhile, PrFT also had a good identifying value for MAFLD as VFA. The area under the curve (95% CI) value of PrFT identifying MAFLD was 0.782 (0.751– 0.812). The optimal cut-off value of PrFT was 12.6mm, with a sensitivity of 77.8% and specificity of 70.8%. Conclusion: PrFT was independently associated with MAFLD, NFS, and FIB-4 and showed a similar identifying value for MAFLD as VFA, which suggested that PrFT can be used as an alternative index to VFA.


  • Open Access

    Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

    by Yan Tong, Jian Qing Huang, Yang Chen, Mei Tu, Wei Wang

    Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM).Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group (n = 120), sitagliptin group (n = 120), and control group (n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety.Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant (p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups (p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025).Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN.Clinical Trial Registration: (https://www.chictr.org.cn/index.aspx), identifier (ChiCTR2200056148).


  • Open Access

    Predicting Value of Perirenal Fat Thickness for Metabolic Syndrome in Patients with Newly-Diagnosed Type 2 Diabetes

    by Xiu Li Guo, Mei Tu, Yang Chen, Wei Wang

    Objective Increasing evidences suggested that perirenal fat thickness (PrFT) was associated with metabolic risk factors, this study aimed to assess the association between PrFT with components of metabolic syndrome (MetS) and explore the value of PrFT in predicting MetS among Newly-Diagnosed type 2 diabetes(T2DM). Method A total of 445 patients with Newly-Diagnosed T2DM from southern China were enrolled into this study. Demographic and anthropometric information were collected. PrFT was evaluated by CT scanning on Revolution VCT 64. Binomial logistic regression analysis and receiver operating characteristics (ROC) curves were conducted to assess the value and optimal cutoff of PrFT for predicting MetS divided by sex. Results The prevalence of MetS was 58.2% in Newly-Diagnosed T2DM.Correlation analysis showed that PrFT was significantly correlated with metabolic risk factors (BMI, WC, TG, HDL-c, SBP, DBP, UA and HOMA-IR). PrFT was also shown to be independently associated with MetS after adjustment for other confounders, the ORs(95%CI) were 1.33(1.01~1.74) in men and 1.53(1.08~2.17) in women(P<0.05). ROC curves showed a good predictive value of PrFT for MetS, the the areas under the curve of ROC values of PrFT predicting MetS were 0.895(95% CI 0.852~0.939) in men and 0.910(95% CI 0.876~0.953) in women(P<0.001). The optimal cut-off values of PrFT were 14.6 mm (sensitivity: 83.8%, specificity: 89.6%) for men and 13.1 mm (sensitivity: 87.6%, specificity: 91.1%) for women. Conclusions PrFT was significantly independent with MetS and showed a powerful predictive value for MetS, which suggested PrFT could be a potential indicator to help clinicians to screen high-risk groups in Newly-Diagnosed T2DM. Clinical Trial Registration: This study was registered in Clinical Trials. Gov (ChiCTR2100052032).

  • Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta‐cell apoptosis via mediating the ASK1/JNK/BAX pathway in rats with type 2 diabetes

    by Wei Wang, Rong Dan Wu, Pin Chen, Xiang Jin Xu, Xiao Zhi Shi, Li Hong Huang, Zhu Lin Shao, Wen Guo

    Objective: Accumulating evidence suggests an association between beta‐cell apoptosis and the ASK1/JNK/BAX pathway. The aim of this study was to investigate the effects of a combined therapy of liraglutide and human umbilical cord mesenchymal stem cells (hUC‐MSCs) on the glucose metabolism and islet beta‐cell apoptosis, and further explore its relationship to the ASK1/JNK/BAX pathway.Method: Type 2 diabetes mellitus (T2DM) rat model was induced by a high‐sugar and high‐fat diet and intraperitoneal injection of low‐dose streptozotocin (STZ) (30 mg/kg). Three days after STZ injection, diabetic rats were randomly treated with subcutaneous injection of liraglutide (200 μg/kg/12 h) for 8 weeks and or hUC‐MSCs (1 × 106/rat) at the first and fifth weeks. Diabetes‐related physical and biochemical parameters, pancreatic histopathological changes, immunohistochemical staining, quantitative real‐time polymerase chain reaction, and western blot were used to measure the expression of apoptosis signal‐regulating kinase 1 (ASK1), Jun N‐terminal kinase (JNK), Bcl‐2 associated X protein (BAX), and B‐cell lymphoma‐2 (Bcl‐2).Results: Eight weeks after liraglutide or human umbilical cord mesenchymal stem cell administration, FPG, HbA1c, glucagon, body weight, and pancreatic ASK1, JNK, and BAX mRNA and proteins were significantly decreased, and the levels of serum C‐p, INS and GLP‐1, ratio of insulin positive area, and Bcl‐2 expression were significantly increased in three treatment groups compared with T2DM group (P<.05).Conclusion: Liraglutide combined with hUC‐MSCs improve glucose metabolism and inhibit islet beta‐cell apoptosis in a ASK1/JNK/BAX pathway‐dependent manner.